Intas Pharma appoints Dr Ajay Kumar Handa as new Executive Vice President - RnD

Ahmedabad: Intas Pharma has announced the appointment of Dr Ajay Kumar Handa as its new Executive Vice President - R&D. The announcement was made via the company’s official LinkedIn page, stating, "We are delighted to welcome Dr Ajay Kumar Handa as Executive Vice President – R&D at Intas Pharmaceuticals." Bringing over three decades of extensive experience in pharmaceutical research and development, Dr. Ajay has spearheaded the advancement of generics and Novel Drug Delivery Systems (NDDS) across diverse dosage forms, including solid orals, liquids, injectables, new chemical entities (NCEs), and dry powder inhalation. Prior to joining Intas, Dr. Handa held several senior leadership roles at major pharmaceutical companies. He served as Executive Vice President and Global Head – OSD at Dr. Reddy's Laboratories, and previously held key R&D positions including President – R&D at Cadila Pharmaceuticals, Senior Vice President at Wockhardt, and Vice President at Zydus Cadila Healthcare. His career also includes impactful tenures at Alembic Pharmaceuticals, Ranbaxy Laboratories, and Panacea Biotec. Intas is a vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide. Intas is currently investing in a higher barrier to entry developments such as Biosimilar and New Chemical Entities. Read also: Intas Pharma Gets Expert Panel Nod For PMS Data On Tofacitinib Ointment In Atopic Dermatitis